BACKGROUND: The Polycomb Repressor Complex (PRC) is an epigenetic regulator of transcription whose action is mediated by 2 protein complexes, PRC1 and PRC2. PRC is oncogenic in glioblastoma, where it is involved in cancer stem cell maintenance and radioresistance. METHODS: We used a set of glioblastoma patient samples, glioma stem cells, and neural stem cells from a mouse model of glioblastoma. We characterized gene/protein expression and cellular phenotypes by quantitative PCR/Western blotting and clonogenic, cell-cycle, and DNA damage assays. We performed overexpression/knockdown studies by lentiviral infection and microRNA/small interfering RNA oligonucleotide transfection. RESULTS: We show that microRNA-128 (miR-128) directly targets mRNA of SUZ12, a key component of PRC2, in addition to BMI1, a component of PRC1 that we previously showed as a target as well. This blocks the partially redundant functions of PRC1/PRC2, thereby significantly reducing PRC activity and its associated histone modifications. MiR-128 and SUZ12/BMI1 show opposite expression in human glioblastomas versus normal brain and in glioma stemlike versus neural stem cells. Furthermore, miR-128 renders glioma stemlike cells less radioresistant by preventing the radiation-induced expression of both PRC components. Finally, miR-128 expression is significantly reduced in neural stem cells from the brain of young, presymptomatic mice in our mouse model of glioblastoma. This suggests that loss of miR-128 expression in brain is an early event in gliomagenesis. Moreover, knockdown of miR-128 expression in nonmalignant mouse and human neural stem cells led to elevated expression of PRC components and increased clonogenicity. CONCLUSIONS: MiR-128 is an important suppressor of PRC activity, and its absence is an early event in gliomagenesis.
BACKGROUND: The Polycomb Repressor Complex (PRC) is an epigenetic regulator of transcription whose action is mediated by 2 protein complexes, PRC1 and PRC2. PRC is oncogenic in glioblastoma, where it is involved in cancer stem cell maintenance and radioresistance. METHODS: We used a set of glioblastomapatient samples, glioma stem cells, and neural stem cells from a mouse model of glioblastoma. We characterized gene/protein expression and cellular phenotypes by quantitative PCR/Western blotting and clonogenic, cell-cycle, and DNA damage assays. We performed overexpression/knockdown studies by lentiviral infection and microRNA/small interfering RNA oligonucleotide transfection. RESULTS: We show that microRNA-128 (miR-128) directly targets mRNA of SUZ12, a key component of PRC2, in addition to BMI1, a component of PRC1 that we previously showed as a target as well. This blocks the partially redundant functions of PRC1/PRC2, thereby significantly reducing PRC activity and its associated histone modifications. MiR-128 and SUZ12/BMI1 show opposite expression in humanglioblastomas versus normal brain and in glioma stemlike versus neural stem cells. Furthermore, miR-128 renders glioma stemlike cells less radioresistant by preventing the radiation-induced expression of both PRC components. Finally, miR-128 expression is significantly reduced in neural stem cells from the brain of young, presymptomatic mice in our mouse model of glioblastoma. This suggests that loss of miR-128 expression in brain is an early event in gliomagenesis. Moreover, knockdown of miR-128 expression in nonmalignant mouse and human neural stem cells led to elevated expression of PRC components and increased clonogenicity. CONCLUSIONS:MiR-128 is an important suppressor of PRC activity, and its absence is an early event in gliomagenesis.
Authors: Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada Journal: Cancer Cell Date: 2005-08 Impact factor: 31.743
Authors: S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace Journal: Biochem Biophys Res Commun Date: 2005-09-09 Impact factor: 3.575
Authors: Martin Leeb; Diego Pasini; Maria Novatchkova; Markus Jaritz; Kristian Helin; Anton Wutz Journal: Genes Dev Date: 2010-02-01 Impact factor: 11.361
Authors: Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Mario-Luca Suvà; Nicolò Riggi; Michalina Janiszewska; Ivan Radovanovic; Paolo Provero; Jean-Christophe Stehle; Karine Baumer; Marie-Aude Le Bitoux; Denis Marino; Luisa Cironi; Victor E Marquez; Virginie Clément; Ivan Stamenkovic Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701
Authors: X U Zhou; Lin Qi; Shiyu Tong; Y U Cui; Jinbo Chen; Tianxiang Huang; Zhi Chen; Xiong-Bing Zu Journal: Oncol Lett Date: 2015-09-09 Impact factor: 2.967
Authors: Alvaro G Alvarado; Soumya M Turaga; Pratheesh Sathyan; Erin E Mulkearns-Hubert; Balint Otvos; Daniel J Silver; James S Hale; William A Flavahan; Pascal O Zinn; Maksim Sinyuk; Meizhang Li; Maheedhara R Guda; Kiran K Velpula; Andrew J Tsung; Ichiro Nakano; Michael A Vogelbaum; Sadhan Majumder; Jeremy N Rich; Justin D Lathia Journal: Neuro Oncol Date: 2015-09-15 Impact factor: 12.300
Authors: Arun K Rooj; Franz Ricklefs; Marco Mineo; Ichiro Nakano; E Antonio Chiocca; Agnieszka Bronisz; Jakub Godlewski Journal: Cell Rep Date: 2017-06-06 Impact factor: 9.423
Authors: Bo Halle; Mads Thomassen; Ranga Venkatesan; Vivek Kaimal; Eric G Marcusson; Sune Munthe; Mia D Sørensen; Charlotte Aaberg-Jessen; Stine S Jensen; Morten Meyer; Torben A Kruse; Helle Christiansen; Steffen Schmidt; Jan Mollenhauer; Mette K Schulz; Claus Andersen; Bjarne W Kristensen Journal: J Neurooncol Date: 2016-04-11 Impact factor: 4.130